Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
28.03.24
21:08 Uhr
50,10 Euro
0,00
0,00 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
49,80050,00028.03.
49,90050,2028.03.

Aktuelle News zur BRISTOL-MYERS SQUIBB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:10After Amgen's stumble, BMS touts KRAS confirmatory trial win for newly bought Krazati1
14:50Bristol Myers Squibb Company: Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes204Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers Squibb NewsroomPRINCETON, NJ / ACCESSWIRE / March 29, 2024...
► Artikel lesen
14:10Bristol Myers Squibb's versatile Zeposia doesn't make the grade in Crohn's disease trial4
10:58Disappointment for BMS as Zeposia fails Crohn's study6
DoBristol Myers' bowel disease drug fails to meet main goal in late-stage study15
DoBristol Myers drug Zeposia fails Phase 3 study for Crohn's disease12
DoIs Bristol Myers Squibb Stock a Buy?32
DiBristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout21
DiBristol Myers Squibb shares positive phase 3 results for Opdivo combination in advanced liver cancer17
MoBristol-Myers Squibb Company (BMY) Impacted by Delay in New Product Launches15
21.03.In his swan song at Bristol Myers Squibb, former CEO Giovanni Caforio pulled down $19.7M31
21.03.Deerfield Agency adds BMS, AbbVie alum as head of media18
21.03.Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer8
21.03.Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma9
21.03.Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion7
21.03.BMS' cell therapy Abecma gains EC approval for multiple myeloma7
20.03.Bristol Myers gets EU approval for Abecma for multiple myeloma9
20.03.After Opdivo flop in liver cancer, Bristol Myers finds Yervoy combo could save lives11
20.03.Bristol Myers liver cancer treatment meets main goal of late-stage study7
20.03.Bristol Myers hits late-stage win for liver cancer therapy4
Seite:  Weiter >>
607 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,51